Health policy experts and legislators are concerned about partnerships between pharmaceutical companies and telehealth providers, raising questions over large fees and discount coupons that may violate federal anti-kickback laws. These concerns matter as they could lead to regulatory scrutiny and potential reforms affecting how tech and pharma industries collaborate on patient care initiatives. Watch for upcoming FDA guidance or enforcement actions regarding these practices.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



